Amplyx Raises $40.5 million to Advance Drug for Deadly Fungal Infections - (Xconomy via NewsPoints Desk)

  • Amplyx Pharmaceuticals announced that it raised $40.5 million in Series B financing to help fund the development of the investigational treatment APX001 for life-threatening fungal infections, Xconomy reported Wednesday.
  • Amplyx CEO Mike Grey noted that APX001 represents a new class of anti-fungal compounds, adding that the FDA has not cleared a new class of anti-fungal therapies since 2011.
  • Amplyx plans to initiate a Phase I trial of APX001 next year before progressing to mid-stage development programmes of the therapy in the treatment of candidiasis, invasive aspergillosis, and certain rare moulds.

To read more NewsPoints articles, click here.